Key facts
- It has raised $2.5M; the latest was Seed Round ($2.5M) in Jun 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Nephrolytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nephrolytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nephrolytics
Developer of an AI-powered clinical evaluation platform designed to provide advanced, actionable insights through a comprehensive platform. The company's platform offers features like enhanced clinical decision support, workflow optimization, data-informed decision-making, strategic financial planning, and more, enabling chronic kidney disease patients to have proactive and personalized care.
- Sector
- Healthcare
- HQ
- Chubbuck, ID, United States
- Founded
- 2023
- Employees
- 23
- Website
- nephrolytics.ai/
- Ownership
- Privately Held (backing)
Nephrolytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nephrolytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nephrolytics in its N-PORT filings yet. We sweep new filings monthly.